Organogenesis (ORGO)
Develops regenerative products for advanced wound care, surgery, and sports medicine.
$1.44
vs last close−0.04 (−3.04%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 109 | 100 | 110 | 130 | 115 | 127 | 87 | 101 | 150 | 225 | 37 | 44 |
| Cost of revenue | 26 | 28 | 29 | 29 | 27 | 31 | 24 | 28 | 36 | 50 | 38 | 24 |
| Gross profit | 83 | 72 | 81 | 101 | 88 | 96 | 63 | 73 | 114 | 175 | −1 | 20 |
| 75 | 73 | 85 | 115 | 82 | 85 | 83 | 84 | 93 | 110 | 64 | 71 | |
| Research & development | 10 | 12 | 13 | 16 | 10 | 12 | 11 | 10 | 13 | 10 | 15 | 18 |
| 64 | 61 | 72 | 77 | 72 | 74 | 73 | 74 | 80 | 100 | 65 | 54 | |
| Selling & marketing | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 70 | 0 | 0 | 0 | 0 | 0 | 54 |
| Other expenses | 0 | 0 | 0 | 23 | 0 | 0 | 0 | 0 | 0 | −1 | −16 | −1 |
| Operating income | 8 | −1 | −4 | −14 | 6 | 10 | −20 | −11 | 22 | 65 | −65 | −51 |
| 0 | −1 | 0 | −1 | 0 | 0 | −6 | −1 | 0 | −2 | −3 | 0 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 0 | 2 | 3 | 0 |
| Income before tax | 8 | −2 | −4 | −15 | 6 | 10 | −26 | −12 | 21 | 63 | −68 | −51 |
| Income tax expense | 4 | −1 | −2 | 3 | −7 | 3 | −7 | −2 | 0 | 20 | −12 | 45 |
| Net income from continuing operations | 3 | −1 | −2 | −17 | 12 | 8 | −19 | −9 | 22 | 44 | −56 | −96 |
| Net income | 3 | −1 | −2 | −17 | 12 | 8 | −19 | −9 | 22 | 44 | −56 | −99 |
| EPS, basic | $0.02 | −$0.00 | −$0.02 | −$0.13 | $0.09 | $0.05 | −$0.17 | −$0.10 | $0.11 | $0.28 | −$0.44 | −$0.77 |
| EPS, diluted | $0.02 | −$0.00 | −$0.02 | −$0.13 | $0.09 | $0.04 | −$0.17 | −$0.10 | $0.11 | $0.27 | −$0.44 | −$0.77 |
| Weighted average shares, basic | 131 | 131 | 132 | 133 | 133 | 132 | 126 | 127 | 127 | 127 | 128 | 129 |
| Weighted average shares, diluted | 133 | 132 | 132 | 133 | 134 | 132 | 126 | 127 | 131 | 132 | 128 | 129 |
| EBITDA | 14 | 11 | 0 | −10 | 11 | 15 | −20 | −5 | 28 | 70 | −56 | −47 |
| Depreciation & amortization | 6 | 12 | 4 | 4 | 4 | 4 | 6 | 7 | 7 | 7 | 12 | 4 |
| EBIT | 8 | −1 | −4 | −14 | 6 | 10 | −26 | −12 | 21 | 63 | −68 | −51 |